Will new MM diagnostic criteria cause confusion in risk stratifying smoldering and active myeloma?

FAQ Library published on June 7, 2016
Download Transcript Download Audio
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Chief Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York

Welcome to Managing Myeloma. My name is Sergio Giralt, and I am the Melvin Berlin Family Chair for Myeloma Research at Memorial Sloan Kettering Cancer Center. I am also a professor of medicine at Weill Cornell Medical College and the chief of the Adult BMT Service at Memorial Hospital in New York City. I am frequently asked, “Will the new diagnostic criteria for multiple myeloma cause confusion between risk of progression assessment, like biomarkers of malignancy, for smoldering myeloma and risk stratification for active myeloma?” The short answer is yes, and that is why this activity in Managing Myeloma is so important. We think that the new criteria of the IMWG will make a significant difference in patients who have very high risk of developing CRAB criteria. Most of us who practice in the field of myeloma would like the patients who are at high risk of developing either calcium abnormalities, renal abnormalities, anemia, or bone disease be identified early and start treatment early before these complications occur. The new SLiM characteristics, or SLiM parameters [≥60% clonal plasma cells by bone marrow biopsy; sFLC involved:uninvolved ratio ≥100; >1 lesion ≥5 mm by MRI] will actually allow us to start treatment early in patients who are expected to develop CRAB criteria within 12 to 24 months. We know that this causes confusion in the field, and we hope that activities such as what we will be doing in Managing Myeloma, will help the practicing physician understand better and provide better treatment for their patients. Thank you for viewing this activity. For additional resources, please view the other educational activities on ManagingMyeloma.com.

Please view the Updated Criteria for the Diagnosis of Multiple Myeloma.

For further information about this important subject, please refer to the related resources and activities on the Managing Myeloma website, as identified below.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Author
Should I wait for the development of CRAB prior to initiating therapy in multiple myeloma patients?
Sergio A. Giralt, MD, FACP
FAQ Library published on October 11, 2016
What are the new NCCN/IMWG recommended baseline workup tests for multiple myeloma?
Sergio A. Giralt, MD, FACP
FAQ Library published on August 3, 2016
What have we learned about the timing of transplant for newly diagnosed MM patients?
Sergio A. Giralt, MD, FACP
FAQ Library published on December 18, 2014
How do I manage the side effects of stem cell transplantation?
Sergio A. Giralt, MD, FACP
FAQ Library published on January 9, 2013 in Stem Cell Transplant, Comorbidities/SEs
Which patients do you consider for delayed transplantation?
Sergio A. Giralt, MD, FACP
FAQ Library published on January 9, 2013 in Stem Cell Transplant
What are the common side effects of melphalan?
Sergio A. Giralt, MD, FACP
FAQ Library published on August 30, 2012 in Comorbidities/SEs
What are the side effects of bendamustine?
Sergio A. Giralt, MD, FACP
FAQ Library published on August 2, 2012 in Comorbidities/SEs
What are the most common side effects of lenalidomide therapy?
Sergio A. Giralt, MD, FACP
FAQ Library published on July 26, 2012 in Comorbidities/SEs, Nurses & Pharmacists
How do I address concerns for patients who “refuse” stem cell transplantation?
Sergio A. Giralt, MD, FACP
FAQ Library published on September 26, 2011 in Stem Cell Transplant, Patient Communication
Is there a subset of patients that would benefit from delayed SCT?
Sergio A. Giralt, MD, FACP
FAQ Library published on September 8, 2011 in Stem Cell Transplant